Minerva Neurosciences, Inc.

NASDAQ:NERV

Biotechnology

Healthcare
$2.18 -6.49%

-$0.30 today

Market cap
$108.64M
Beta
-0.11
P/E (TTM)
-0.2
EPS (TTM)
-$8.46
52W Low $1.76High $12.46

Volume 0.28M

Average 0.21M

NERV Common Stock Repurchased

Cash spent buying back the company's own shares.

Minerva Neurosciences, Inc.NASDAQ: NERV

Common Stock Repurchased · Q2 FY2026 · quarter ended Jun 2026

Common stock repurchased outflow grows to $0

Q2 FY2026 common stock repurchased was $0, compared with $0 a year earlier. Trailing-twelve-month common stock repurchased was $0.

Context

  • Common stock repurchased increased in 0 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly common stock repurchased holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterJun 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
LTMJun 2026
$0— YoY
Common Stock Repurchased past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Common Stock Repurchased history

USD · from the cash flow

Latest · FY2025
0 USD
Year-over-year change
—

Common Stock Repurchased vs competitors

How NERV compares with its peers on the latest reported figures

  • NERV's LTM Jun 2026 common stock repurchased of $0 is the 2nd largest of the 4 companies compared; the peer median is $0.
NERV Competitors Peer median
Common Stock Repurchased for NERV and competitors
Company Period LTM YoY 3-year CAGR% of revenue
RLYBRallybio CorporationLTM Mar 2026$10K -44.4%—1.2%
NERVMinerva Neurosciences, Inc.LTM Jun 2026$0 ———
NRXSNeurAxis, Inc.LTM Mar 2026$0 ——0.0%
ENLVEnlivex Therapeutics Ltd.LTM Dec 2025$0 ———
Peer median (excluding NERV) $0-44.4%—0.6%

Competitors are the stored peer set for NERV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(49.91M)(32.11M)(30.01M)1.44M(293.42M)
Depreciation & Amortization101.79K8.51K30.98K22.47K5.44M
Deferred Income Tax(1.8M)0000
Stock-Based Compensation5.22M4.11M1.97M1.33M1.33B
Change in Working Capital259.34K(4.06M)4.94M(320.6K)(632.35K)
Accounts Receivables00000
Inventory00000
Accounts Payables857.6K(883.55K)835.65K(197.48K)(1.06M)
Other Working Capital(598.27K)(3.18M)4.1M(123.13K)426.67K
Other Non-Cash Items21.53M7.41M8.28M(22.02M)(14.55B)
Operating Cash Flow(24.6M)(24.65M)(14.78M)(19.55M)(13.51B)
Capital Expenditures0(16.33K)000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow0(16.33K)000
Debt Repayment00000
Common Stock Issued0020M074.45M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities60M(5)(396.29K)074.38B
Financing Cash Flow60M(5)19.6M074.45B
Effect of Forex Changes00000
Net Change in Cash35.4M(24.66M)4.82M(19.55M)60.94B
Free Cash Flow(24.6M)(24.66M)(14.78M)(19.55M)(13.51B)

Minerva Neurosciences, Inc.

NASDAQ:NERV

Intrinsic Alpha fair value

Locked

Current Price

$2.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.